Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and ...

The company imports some of its active pharmaceutical ingredient, or semaglutide, into the U.S. for its blockbuster diabetes ...

(Bloomberg) -- The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares ...

The healthcare company's pivot into a new set of technologies will have many implications for the stock.

We recently made a list of the 10 Best Global Stocks To Buy Now. In this piece, we will look at where Novo Nordisk A/S ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

A committee report found the weight loss drug is offered for less than $100 in some European countries, compared to monthly ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Investing.com – Denmark stocks were lower after the close on Tuesday, as losses in the Oil & Gas, Healthcare and Personal & Household Goods sectors led shares lower ...